Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study
David R. Gandara(University of California, Davis), Joachim von Pawel(Asklepios Fachkliniken München-Gauting), Julien Mazières(Université Fédérale de Toulouse Midi-Pyrénées), Richard Sullivan(Auckland City Hospital), Åslaug Helland(University of Oslo), Ji‐Youn Han(National Cancer Center), Santiago Ponce Aix(Hospital Universitario 12 De Octubre), Achim Rittmeyer, Fabrice Barlési(Assistance Publique Hôpitaux de Marseille), Toshio Kubo(Okayama University Hospital), Keunchil Park(Sungkyunkwan University), Jerome H. Goldschmidt(Mountain Blue Cancer Care Center), Mayank Gandhi, Cindy Yun, Wei Yu, Christina Matheny, Pei He(Mountain Blue Cancer Care Center), Alan Sandler, Marcus Ballinger, Louis Fehrenbacher(Kaiser Permanente Vallejo Medical Center)
Cited by 159Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis